Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 16/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663327 | 0.89 | ENPP1 (0.86) | ENPP1TDP1MAPTTP53L3MBTL1 | |
| SCHEMBL23120290 | 0.89 | ENPP1 (0.86) | ENPP1TDP1MAPTTP53L3MBTL1 | |
| SCHEMBL24846219 | 0.84 | ENPP1 (0.79) | ENPP1MAPTTP53L3MBTL1 | |
| SCHEMBL24847293 | 0.83 | ENPP1 (0.80) | ENPP1TDP1MAPTTP53L3MBTL1 | |
| SCHEMBL24846220 | 0.83 | ENPP1 (0.80) | ENPP1TDP1MAPTTP53L3MBTL1 | |
| SCHEMBL24847225 | 0.83 | ENPP1 (0.83) | ENPP1TDP1MAPTTP53L3MBTL1 | |
| SCHEMBL24847296 | 0.82 | ENPP1 (0.78) | ENPP1TDP1MAPTTP53L3MBTL1 | |
| SCHEMBL24846218 | 0.82 | ENPP1 (0.78) | ENPP1TDP1MAPTTP53L3MBTL1 | |
| SCHEMBL24846217 | 0.82 | ENPP1 (0.81) | ENPP1L3MBTL1 | |
| SCHEMBL24846483 | 0.81 | ENPP1 (0.70) | ENPP1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002387-A1 | 2-AMINO-S6-SUBSTITUTED THIOPURINE COMPOUNDS AS INHIBITORS OF THE ENPP1 PROTEIN | ATEN PORUS LIFESCIENCES PVT. LTD. (IN) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002387-A1 | 2-AMINO-S6-SUBSTITUTED THIOPURINE COMPOUNDS AS INHIBITORS OF THE ENPP1 PROTEIN | ENPP1, ENPP3, PNP | ENPP1 1/4885TDP1 244/4885MAPT 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.